[go: up one dir, main page]

MX2023011269A - Inhibidores del inflamasoma nlrp3. - Google Patents

Inhibidores del inflamasoma nlrp3.

Info

Publication number
MX2023011269A
MX2023011269A MX2023011269A MX2023011269A MX2023011269A MX 2023011269 A MX2023011269 A MX 2023011269A MX 2023011269 A MX2023011269 A MX 2023011269A MX 2023011269 A MX2023011269 A MX 2023011269A MX 2023011269 A MX2023011269 A MX 2023011269A
Authority
MX
Mexico
Prior art keywords
inhibitors
nlrp3
compounds
aging
inflamasome
Prior art date
Application number
MX2023011269A
Other languages
English (en)
Inventor
George Hartman
Xu He
Jia Du
Lifang Zhang
Paul Humphries
Kevin Edward Leif Wilhelmsen
Original Assignee
Bioage Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioage Labs Inc filed Critical Bioage Labs Inc
Publication of MX2023011269A publication Critical patent/MX2023011269A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente descripción está relacionada con compuestos que actúan como inhibidores de inflamasomas NLRP3; composiciones farmacéuticas que comprenden los compuestos; y métodos de tratamiento de trastornos asociados a la inflamación y el envejecimiento inflamatorio, lo cual incluye la pérdida de la audición y otras enfermedades asociadas al envejecimiento.
MX2023011269A 2021-03-23 2022-03-23 Inhibidores del inflamasoma nlrp3. MX2023011269A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163164780P 2021-03-23 2021-03-23
US202163219538P 2021-07-08 2021-07-08
PCT/US2022/021461 WO2022204227A1 (en) 2021-03-23 2022-03-23 Inhibitors of nlrp3 inflammasome

Publications (1)

Publication Number Publication Date
MX2023011269A true MX2023011269A (es) 2024-01-17

Family

ID=81325267

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011269A MX2023011269A (es) 2021-03-23 2022-03-23 Inhibidores del inflamasoma nlrp3.

Country Status (13)

Country Link
US (6) US11702391B2 (es)
EP (1) EP4313302A1 (es)
JP (1) JP2024511204A (es)
KR (1) KR20240019754A (es)
AU (1) AU2022241754A1 (es)
BR (1) BR112023019211A2 (es)
CA (1) CA3210389A1 (es)
CL (2) CL2023002786A1 (es)
CO (1) CO2023013990A2 (es)
IL (1) IL306022A (es)
MX (1) MX2023011269A (es)
TW (1) TW202304865A (es)
WO (1) WO2022204227A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024511204A (ja) 2021-03-23 2024-03-12 バイオエイジ ラブス， インコーポレイテッド Ｎｌｒｐ３インフラマソームの阻害剤
JP2025504008A (ja) 2022-01-28 2025-02-06 バイオエイジ ラブス， インコーポレイテッド Ｎｌｒｐ３インフラマソームのｎ－オキシド阻害剤
WO2024064655A1 (en) * 2022-09-20 2024-03-28 BioAge Labs, Inc. Indazole and pyrazolopyridine compounds as inhibitors of nlrp3 inflammasome
TW202502344A (zh) 2023-06-02 2025-01-16 美商默沙東有限責任公司 作為nod樣受體蛋白3抑制劑之5,6不飽和雙環雜環
US20250084080A1 (en) * 2023-09-12 2025-03-13 BioAge Labs, Inc. Crystalline and salt forms of an nlrp3 inhibitor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0310724D0 (en) 2003-05-09 2003-06-11 Glaxo Group Ltd Chemical compounds
EP1878730A1 (en) * 2006-07-12 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same
EP2269990A4 (en) 2008-03-25 2012-04-18 Takeda Pharmaceutical Heterocyclic compound
GB201101517D0 (en) 2011-01-28 2011-03-16 Proximagen Ltd Receptor antagonists
ES2656972T3 (es) * 2012-02-23 2018-03-01 Vanderbilt University Análogos de 5-aminotieno [2,3-c] piridazin-6-carboxamida como moduladores alostéricos positivos del receptor de acetilcolina muscarínico M4
MX381180B (es) 2014-11-18 2025-03-12 Merck Sharp & Dohme Compuestos aminopirazina con propiedades antagonistas a2a.
CN111303070B (zh) 2017-06-26 2024-02-23 中国科学技术大学 噻唑啉酮杂环化合物、其制备方法以及药用组合物
US11230541B2 (en) 2017-07-28 2022-01-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
GB201805527D0 (en) 2018-04-04 2018-05-16 Mironid Ltd Compounds and their use as pde4 activators
AU2019375983A1 (en) * 2018-11-09 2021-06-10 Vivace Therapeutics, Inc. Bicyclic compounds
CN111329993A (zh) 2020-03-09 2020-06-26 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 一种nlrp3炎症小体抑制剂及其应用
JP2024511204A (ja) * 2021-03-23 2024-03-12 バイオエイジ ラブス， インコーポレイテッド Ｎｌｒｐ３インフラマソームの阻害剤
JP2025504008A (ja) * 2022-01-28 2025-02-06 バイオエイジ ラブス， インコーポレイテッド Ｎｌｒｐ３インフラマソームのｎ－オキシド阻害剤
WO2024064655A1 (en) * 2022-09-20 2024-03-28 BioAge Labs, Inc. Indazole and pyrazolopyridine compounds as inhibitors of nlrp3 inflammasome

Also Published As

Publication number Publication date
WO2022204227A1 (en) 2022-09-29
BR112023019211A2 (pt) 2023-11-28
KR20240019754A (ko) 2024-02-14
US20240067610A1 (en) 2024-02-29
US11702391B2 (en) 2023-07-18
CL2023002786A1 (es) 2024-02-02
US20220324812A1 (en) 2022-10-13
US20240059659A1 (en) 2024-02-22
US20240051923A1 (en) 2024-02-15
CA3210389A1 (en) 2022-09-29
US11708334B2 (en) 2023-07-25
US20230365507A1 (en) 2023-11-16
CO2023013990A2 (es) 2024-02-15
CL2024001313A1 (es) 2024-10-11
US20230051130A1 (en) 2023-02-16
TW202304865A (zh) 2023-02-01
JP2024511204A (ja) 2024-03-12
EP4313302A1 (en) 2024-02-07
IL306022A (en) 2023-11-01
US12215087B2 (en) 2025-02-04
AU2022241754A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
MX2023011269A (es) Inhibidores del inflamasoma nlrp3.
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
CO2020005887A2 (es) Compuestos policíclicos como inhibidores alostéricos de shp2
CL2017001984A1 (es) Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr).(solicitud divisional 3355-2014)
ECSP24035717A (es) Compuestos de quinolina como inhibidores de kras
CO2024001285A2 (es) Compuestos tricíclicos como inhibidores de kras
MX2024012801A (es) Inhibidores de parp1 de azetidina y pirrolidina y usos de estos
BR112015029240A2 (pt) composto, composição e método de evitar ou tratar inflamação associada com inflamassoma nrlp3 em um indivíduo
GT201500294A (es) Compuestos de biaril-amida como inhibidores de cinasa
GT201700107A (es) Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y oesteoartritis
PH12019501323A1 (en) Compositions comprising sulfated polysaccharides
CO2019007409A2 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos
CU24627B1 (es) Derivados de imidazolidin-2-ona sustituidos como inhibidores de prmt5
MX2015003239A (es) Composiciones topicas y metodos de uso.
CL2019002079A1 (es) Sales del inhibidor de pim quinasa; útiles en el tratamiento del cáncer. (divisional solicitud 201800611)
MX2022008478A (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
CL2023001637A1 (es) Inhibidores de la vía jak1 para el tratamiento del vitíligo.
EA201791814A1 (ru) Имидазолильные трициклические еноны как антиоксидантные модуляторы воспаления
MX2024015493A (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1
MX2022000781A (es) Triterpenoides sintéticos heteroaromáticos sustituidos polarmente en c17, y métodos de uso de los mismos.
AR130528A1 (es) Compuestos indazol y pirazolpiridina como inhibidores del inflamasoma nlrp3
MX2022003398A (es) Composicion micelar inmunoestimulante.
CL2023002064A1 (es) Derivados de ácido urólico sintético y métodos de uso de estos
CL2020000127A1 (es) Moduladores terapéuticos del modo inverso de la atp sintasa.
MX2021011979A (es) Derivados del isocromeno como inhibidores de la fosfoinositida 3-cinasa.